NITO (N2OFF, Inc. Common Stock) Stock Analysis - News

N2OFF, Inc. Common Stock (NITO) is a publicly traded Basic Materials sector company. As of May 21, 2026, NITO trades at $1.22 with a market cap of $3.31M and a P/E ratio of -0.34. NITO moved +29.10% today. Year to date, NITO is -71.50%; over the trailing twelve months it is -93.93%. Its 52-week range spans $0.77 to $122.15. Rallies surfaces NITO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in NITO news today?

N2OFF to Become Nexentis with New Trading Symbol, Biotech Focus: N2OFF will change its name to Nexentis Technologies and ticker to NXTS on Nasdaq on Feb. 26, 2026, reflecting its transformation into an AI-driven computational biotech platform. The company completed acquisition of MitoCareX, integrating its MITOLINE™ discovery engine to develop mitochondrial-targeted oncology and anti-inflammatory drug candidates.

NITO Key Metrics

Key financial metrics for NITO
MetricValue
Price$1.22
Market Cap$3.31M
P/E Ratio-0.34
EPS$-3.54
Dividend Yield0.00%
52-Week High$122.15
52-Week Low$0.77
Volume1.64M
Avg Volume0
Revenue (TTM)$0
Net Income$-4.16M
Gross Margin0.00%

Latest NITO News

NITO Analyst Consensus

NITO analyst coverage data. Average price target: $0.00.

Common questions about NITO

What changed in NITO news today?
N2OFF to Become Nexentis with New Trading Symbol, Biotech Focus: N2OFF will change its name to Nexentis Technologies and ticker to NXTS on Nasdaq on Feb. 26, 2026, reflecting its transformation into an AI-driven computational biotech platform. The company completed acquisition of MitoCareX, integrating its MITOLINE™ discovery engine to develop mitochondrial-targeted oncology and anti-inflammatory drug candidates.
Does Rallies summarize NITO news?
Yes. Rallies summarizes NITO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is NITO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NITO. It does not provide personalized investment advice.
NITO

NITO